Galapagos progresses with its JAK1 inhibitor in RA
This article was originally published in Scrip
Executive Summary
Belgium's Galapagos has started a Phase II trial for its oral JAK 1 inhibitor, GLPG0634, for rheumatoid arthritis (RA), which it expects to complete by the end of 2011.